Cowen P J, Fraser S, Grahame-Smith D G, Green A R, Stanford C
Br J Pharmacol. 1983 Jan;78(1):89-96. doi: 10.1111/j.1476-5381.1983.tb09367.x.
1 The beta-adrenoceptor agonist, isoprenaline (1.5-3.0 mg kg(-1) intravenously), produced a dose-related increase in rat pineal melatonin content. This increase was prevented by pretreatment with the selective beta(1)-adrenoceptor antagonist, atenolol (2 mg kg(-1)), but not by the beta(2)-adrenoceptor antagonist, butoxamine (2 mg kg(-1)). The beta(2)-adrenoceptor agonist, terbutaline (5.0 mg kg(-1)), produced a moderate increase in pineal melatonin content.2 Repeated daily administration of desmethylimipramine (10 mg kg(-1) for 10 days) and maprotiline (10 mg kg(-1) for 10 days), antidepressants predominantly inhibiting noradrenaline (NA) uptake, reduced the isoprenaline-induced increase in pineal melatonin content. Amitriptyline (20 mg kg(-1) for 14 days), a drug which inhibits both NA and 5-hydroxytryptamine (5-HT) uptake, had a similar effect. The beta-adrenoceptor agonist, clenbuterol (5 mg kg(-1) for 14 days), also attenuated the increase in pineal melatonin produced by isoprenaline.3 In contrast, chronic administration of the selective 5-HT uptake inhibitor, fluoxetine (10 mg kg(-1) for 10 days), or the antidepressants, iprindole and mianserin (both 20 mg kg(-1) for 14 days), which do not inhibit monoamine uptake, failed to reduce the increase in pineal melatonin following isoprenaline. Repeated electroconvulsive shock was similarly without effect.4 Ten hours after the final dose of desmethylimipramine (10 mg kg(-1)) once daily for 10 days there was no change in the usual dark phase increase in pineal melatonin.5 The data suggest that repeated administration of certain antidepressant drugs results in reduced pineal beta-adrenoceptor sensitivity. However the lack of change in the dark phase increase in pineal melatonin following repeated desmethylimipramine, implies that the reduced ss-adrenoceptor sensitivity may be part of an adaptive process which maintains normal pineal function. Therefore the decrease in beta-adrenoceptor number in the brain reported after chronic antidepressant administration may not be associated with a change in overall synaptic function.
β - 肾上腺素能受体激动剂异丙肾上腺素(静脉注射1.5 - 3.0毫克/千克)可使大鼠松果体褪黑素含量呈剂量依赖性增加。这种增加可被选择性β(1) - 肾上腺素能受体拮抗剂阿替洛尔(2毫克/千克)预处理所阻断,但不能被β(2) - 肾上腺素能受体拮抗剂布托沙明(2毫克/千克)阻断。β(2) - 肾上腺素能受体激动剂特布他林(5.0毫克/千克)可使松果体褪黑素含量适度增加。
每天重复给予去甲丙咪嗪(10毫克/千克,共10天)和马普替林(10毫克/千克,共10天),这两种主要抑制去甲肾上腺素(NA)摄取的抗抑郁药,可降低异丙肾上腺素诱导的松果体褪黑素含量增加。阿米替林(20毫克/千克,共14天),一种同时抑制NA和5 - 羟色胺(5 - HT)摄取的药物,也有类似作用。β - 肾上腺素能受体激动剂克仑特罗(5毫克/千克,共14天)也可减弱异丙肾上腺素引起的松果体褪黑素增加。
相比之下,长期给予选择性5 - HT摄取抑制剂氟西汀(10毫克/千克,共10天),或不抑制单胺摄取的抗抑郁药伊普吲哚和米安色林(均为20毫克/千克,共14天),未能降低异丙肾上腺素后松果体褪黑素的增加。重复电休克同样无效。
每天一次给予去甲丙咪嗪(10毫克/千克),共10天,在最后一剂给药10小时后,松果体褪黑素在通常的黑暗期增加没有变化。
数据表明,重复给予某些抗抑郁药会导致松果体β - 肾上腺素能受体敏感性降低。然而,重复给予去甲丙咪嗪后松果体褪黑素在黑暗期增加没有变化,这意味着β - 肾上腺素能受体敏感性降低可能是维持正常松果体功能的适应性过程的一部分。因此,长期给予抗抑郁药后大脑中β - 肾上腺素能受体数量的减少可能与整体突触功能的变化无关。